Do small interfering RNA (siRNA) therapies reduce triglycerides and improve lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia?
Patients with hypertriglyceridemia (HTG) and mixed dyslipidemia
Small interfering RNA (siRNA) therapies (including APOC3-targeted and ANGPTL3-targeted treatments)
Reduction in triglycerides, improvement in lipid profiles (including HDL-C and LDL-C), and safetysurrogate
siRNA therapies targeting APOC3 and ANGPTL3 are effective and safe for reducing triglycerides and modulating broader lipid profiles in patients with hypertriglyceridemia and mixed dyslipidemia.
siRNA therapies demonstrate significant efficacy in reducing triglycerides and improving lipid profiles in patients with HTG and mixed dyslipidemia. APOC3-targeted treatments primarily reduce triglycerides while increasing HDL-C, whereas ANGPTL3-targeted therapies offer broader lipid modulation, including substantial reductions in LDL-C. Both therapies demonstrate favorable safety profiles.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yifan Gao
Yanmin Bai
Xu Mu
SHILAP Revista de lepidopterología
Frontiers in Pharmacology
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Building similarity graph...
Analyzing shared references across papers
Loading...
Gao et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69cdfe8b132ef1ca83ea47fe — DOI: https://doi.org/10.3389/fphar.2026.1736821